MedPath

Compare of Surgical Condition and Complications With Moderate and Deep NM Block

Not Applicable
Conditions
Neuromuscular Blockade
Interventions
Drug: cis-atracurium
Registration Number
NCT02601508
Lead Sponsor
Chonnam National University Hospital
Brief Summary

This study is designed to evaluate the surgeon's satisfaction with either deep or moderate neuromuscular blockade during laparoscopic gastrectomy surgery and observe the recovery profiles in the recovery room and the ward.The explorative objective of this study is to evaluate the safety profiles of deep and moderate neuromuscular blockades via observation of postoperative complications.

Detailed Description

Neuromuscular blocking agents (NMBAs) are frequently using during anesthesia to facilitate tracheal intubation and to improve surgical conditions. In an adequately anesthetized and monitored patient, the presence of one or two responses in the train-of-four (TOF) pattern normally indicates sufficient relaxation for most surgical procedures in general practices. It has been called moderate neuromuscular blockade (mNMB) condition. Nowadays, laparoscopic surgeries have expanded impressively into various areas of surgeries, both in scope and volume. If any hypothetical advantages of deep neuromuscular blockade (dNMB) during laparoscopic surgery turned out to be realized in practice with sufficient supporting evidence, it would become an important anesthetic option for better patient outcomes.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
80
Inclusion Criteria
  • All adult (≥ 20 years of age) patients scheduled for an elective laparoscopic gastrectomy who have signed the written informed consent.
Exclusion Criteria
  • Known allergy to rocuronuim, cisatracurium or sugammadex
  • Significant liver or kidney dysfunction
  • Any neuromuscular disease
  • Pregnant or breast feeding
  • Indication for rapid sequence induction
  • Inability to give informed consent
  • Patients taking any medication with potential interference with neuromuscular transmission

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Modarate Blockade Groupcis-atracuriumNeuromuscular blocking agent, cis-atracurium will be administered after skin incision and reversal agents, pyridostigmine \& glycopyrrolate will be given for the recovery.
Deep Blockade GroupRocuroniumNeuromuscular blocking agent, rocuronium will be administered after skin incision and reversal agent, Sugammadex will be given for the recovery.
Primary Outcome Measures
NameTimeMethod
Surgical rating SCORE(SRS)every 15 minutes from the pneumoperitoneum, up to 120 minutes till the end of surgery

excellent (5), good but not optimal (4), moderate (3), poor but acceptable (2) or poor and unacceptable (1)

Secondary Outcome Measures
NameTimeMethod
Respiratory rateevery 15 minutes from the arrival on the recovery room, up to 60 minutes

Respiratory rate of patient

peripheral arterial oxygen saturationevery 15 minutes from the arrival on the recovery room, up to 60 minutes

peripheral arterial oxygen saturation(sPO2)

visual analogue scale (VAS) for painevery 15 minutes from the arrival on the recovery room, up to 60 minutes

visual analogue scale (VAS) for pain

occurrence of nausea or vomitingevery 15 minutes from the arrival on the recovery room, up to 60 minutes

occurrence of nausea or vomiting with Rhodes Index

the level of sedation or alertnessevery 15 minutes from the arrival on the recovery room, up to 60 minutes

the level of sedation or alertness with OAA/S scale

Postoperative Quality Recovery Scale (PQRS)at baseline (the day before surgery), at 1 hour after surgery, at 6 hours after surgery, at 24 hours after surgery and at 7 days after surgery

physiologic, nociceptive, emotive, cognitive and activities of daily living

Trial Locations

Locations (1)

Chonnam University Hwasun Hospital

🇰🇷

Hwasun, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath